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a b s t r a c t
The design and synthesis of a small library of pyrrolidine iminocyclitol inhibitors with a structural sim-
ilarity to 1,4-dideoxy-1,4-imino-D-arabitol (DAB-1) is reported. This library was speciﬁcally designed to
gain a better insight into the mechanism of inhibition of glycosidases by polyhydroxylated pyrrolidines
or iminocyclitols. Pyrrolidine-3,4-diol 15a and pyrrolidine-3,4-diol diacetate 15b had emerged as the
most potent a-glucosidase inhibitors in the series. Docking studies performed with an homology model
of a-glucosidase disclosed binding poses for compounds 15a, 15b, 16a, and 16a0 occupying the same
region as the NH group of the terminal ring of acarbose and suggest a closer and stronger binding of com-
pound 15a and 15b with the enzyme active site residues. Our studies indicate that 2 or 5-hydroxyl sub-
stituents appear to be vital for high inhibitory activity.
 2013 Elsevier Ltd. All rights reserved.
1. Introduction
The iminocyclitols—polyhydroxylated pyrrolidines and piperi-
dines—are a family of important pharmacologically active com-
pounds that are both potent glycosidase and glycosyltransferase
inhibitors due to their mimicry of the transition state of the enzy-
matic reaction, including serendipitous electrostatic binding inter-
actions.1,2 For this reason, they have been selected as therapeutic
agents in several areas such as cancer, viral infections (particularly
inﬂuenza) and diabetes, etc. For example, deoxinojirimicin (DNJ) 1
is an inhibitor of endoplasmic reticulum a-glucosidases I,3 and
1,4-dideoxy-1,4-imino-D-arabinitol (DAB-1) 2 and 2,5-dideoxy-
2,5-imino-D-mannitol (DMDP) 35 are powerful inhibitors of
a-glucosidases4 (Fig. 1). The synthesis of more potent novel
analogues of these compounds is an important goal in medicinal
chemistry, not only for targeting human disease, but also as tools
to probe the mechanism of glucosidase function. In most cases,
these molecules function as pure enantiomers.
It has been previously pointed out that structure–activity rela-
tionships for iminocyclitol glycosidase inhibitors are difﬁcult to
elucidate, making rational inhibitor design a difﬁcult task.1 It is
also known that ﬁve-membered iminocyclitols can give rise to
higher inhibition than their six-membered counterparts and subtle
selectivities may be observed for ﬁve- over six-membered systems,
thus making logical design based upon structural analogy difﬁ-
cult.6 For this reason many types of ﬁve-membered iminocyclitols
have been synthesized and screened. An examination of the litera-
ture showed that a number of diverse structural types have been
screened for a-glucosidase inhibition. This includes those devel-
oped by Davis, for example, 46 (Fig. 1) obtained from 3-pyrroline
and tartaric acid, and showed no signiﬁcant inhibition (3–13% at
the 1 mM level). The ﬁve-membered iminocyclitol amide deriva-
tives 5 developed by Wong’s group showed inhibition with a Ki va-
lue of 53 nM7 (which was better than that exhibited by the parent
structure 6) and the 2-alkylated analogues of type 7 (Fig. 1) were
also shown by Wong1b to be weak a-glucosidase inhibitors
(3–54% inhibition at 200 lM). Davis has also shown that a library
of N-acyl(aroyl)-2-carboxyamide substituted pyrrolidine imino-
cyclitols of type 8, showed little or no inhibition at 100 lM.8 Wong
has prepared and tested pyrrolidine iminocyclitols of type 9 with
side-chains in both the 2 and the 5 positions,9 in which some were
very potent inhibitors. Calveras et al.10 showed that a library of
iminocyclitols of type 10 inhibited this enzyme at 1.6–4.2 nM level.
In most cases the presence of a hydroxymethyl appendage seems
to give signiﬁcant inhibition, whereas when substituted by an alkyl
group, as in 4 and 7 (Fig. 1), the inhibition is weaker or even absent,
indicating that this substituent must be relevant to approximate
the structures of the natural a-glucosidase sugar substrate.6 This
point has been echoed by Wong9 and indeed, this hypothesis has
been supported somewhat by the work of both Bols11 and Lundt,12
who prepared the 2,5-non-substituted pyrrolidine iminocyclitols
11, 12 and 13, with the hydroxymethyl appendage transposed to
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